Hear from an Ionis Rare Disease Account Specialist

Fill out the form below to request to connect with an Ionis Rare Disease Account Specialist and receive the latest news on DAWNZERA.

* Required fields

By clicking the submit button, I agree that Ionis and its subsidiaries may use the information I'm submitting to contact me with information about DAWNZERATM. I understand that all personal information I've submitted will be used in accordance with Ionis' Privacy Policy and I agree to the Terms of Use. To manage your marketing preferences, go to Your Privacy Choices.

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

DAWNZERA is contraindicated in patients with a history of serious hypersensitivity reactions, including anaphylaxis, to donidalorsen or any of the excipients in DAWNZERA.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with DAWNZERA. If signs and symptoms of serious hypersensitivity reactions occur, discontinue DAWNZERA and institute appropriate therapy.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥ 5%) are injection site reactions, upper respiratory tract infection, urinary tract infection, and abdominal discomfort.

INDICATION

DAWNZERA (donidalorsen) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Please see full Prescribing Information for DAWNZERA.